vs
Immunovant, Inc.（IMVT）与Maase Inc.（MAAS）财务数据对比。点击上方公司名可切换其他公司
Maase Inc.的季度营收约是Immunovant, Inc.的1.2倍（$9.9M vs $8.4M），Maase Inc.自由现金流更多（$-18.3M vs $-59.8M）
Immunovant是一家临床阶段生物制药企业，专注于开发用于治疗严重、罕见自身免疫性疾病及炎症性疾病的新型单克隆抗体疗法，其核心在研候选产品覆盖多种自身免疫适应症，面向全球医疗市场布局研发管线。
IMVT vs MAAS — 直观对比
营收规模更大
MAAS
是对方的1.2倍
$8.4M
自由现金流更多
MAAS
多$41.6M
$-59.8M
损益表 — Q4 FY2024 vs Q2 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $9.9M |
| 净利润 | $-75.3M | — |
| 毛利率 | — | 78.7% |
| 营业利润率 | -896.2% | -55.9% |
| 净利率 | -899.0% | — |
| 营收同比 | 140.7% | — |
| 净利润同比 | -26.7% | — |
| 每股收益（稀释后） | $-0.50 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMVTMAAS
| Q1 24 | $8.4M | — | ||
| Q4 23 | $8.9M | — | ||
| Q3 23 | $3.6M | — | ||
| Q2 23 | $4.1M | — | ||
| Q1 23 | $3.5M | — | ||
| Q4 22 | $2.9M | $9.9M | ||
| Q3 22 | $1.2M | — | ||
| Q2 22 | $0 | — |
净利润IMVTMAAS
| Q1 24 | $-75.3M | — | ||
| Q4 23 | $-51.4M | — | ||
| Q3 23 | $-58.7M | — | ||
| Q2 23 | $-73.9M | — | ||
| Q1 23 | $-59.4M | — | ||
| Q4 22 | $-63.2M | — | ||
| Q3 22 | $-47.9M | — | ||
| Q2 22 | $-40.4M | — |
毛利率IMVTMAAS
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | 78.7% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
营业利润率IMVTMAAS
| Q1 24 | -896.2% | — | ||
| Q4 23 | -576.8% | — | ||
| Q3 23 | -1629.6% | — | ||
| Q2 23 | -1819.1% | — | ||
| Q1 23 | -1736.3% | — | ||
| Q4 22 | -2134.5% | -55.9% | ||
| Q3 22 | -4130.6% | — | ||
| Q2 22 | — | — |
净利率IMVTMAAS
| Q1 24 | -899.0% | — | ||
| Q4 23 | -575.6% | — | ||
| Q3 23 | -1642.3% | — | ||
| Q2 23 | -1818.9% | — | ||
| Q1 23 | -1707.8% | — | ||
| Q4 22 | -2147.7% | — | ||
| Q3 22 | -4153.2% | — | ||
| Q2 22 | — | — |
每股收益（稀释后）IMVTMAAS
| Q1 24 | $-0.50 | — | ||
| Q4 23 | $-0.36 | — | ||
| Q3 23 | $-0.45 | — | ||
| Q2 23 | $-0.57 | — | ||
| Q1 23 | $-0.46 | — | ||
| Q4 22 | $-0.49 | — | ||
| Q3 22 | $-0.41 | — | ||
| Q2 22 | $-0.35 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $635.4M | $10.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $617.8M | $31.6M |
| 总资产 | $666.4M | $47.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMVTMAAS
| Q1 24 | $635.4M | — | ||
| Q4 23 | $690.9M | — | ||
| Q3 23 | $269.9M | — | ||
| Q2 23 | $330.0M | — | ||
| Q1 23 | $376.5M | — | ||
| Q4 22 | $432.6M | $10.9M | ||
| Q3 22 | $405.8M | — | ||
| Q2 22 | $427.2M | — |
股东权益IMVTMAAS
| Q1 24 | $617.8M | — | ||
| Q4 23 | $679.3M | — | ||
| Q3 23 | $251.8M | — | ||
| Q2 23 | $299.9M | — | ||
| Q1 23 | $362.5M | — | ||
| Q4 22 | $414.7M | $31.6M | ||
| Q3 22 | $395.7M | — | ||
| Q2 22 | $436.5M | — |
总资产IMVTMAAS
| Q1 24 | $666.4M | — | ||
| Q4 23 | $711.4M | — | ||
| Q3 23 | $292.1M | — | ||
| Q2 23 | $351.2M | — | ||
| Q1 23 | $405.8M | — | ||
| Q4 22 | $456.2M | $47.0M | ||
| Q3 22 | $428.1M | — | ||
| Q2 22 | $458.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-59.7M | $-18.2M |
| 自由现金流经营现金流 - 资本支出 | $-59.8M | $-18.3M |
| 自由现金流率自由现金流/营收 | -714.4% | -184.4% |
| 资本支出强度资本支出/营收 | 1.8% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-214.6M | — |
8季度趋势，按日历期对齐
经营现金流IMVTMAAS
| Q1 24 | $-59.7M | — | ||
| Q4 23 | $-47.1M | — | ||
| Q3 23 | $-60.1M | — | ||
| Q2 23 | $-47.4M | — | ||
| Q1 23 | $-55.8M | — | ||
| Q4 22 | $-46.4M | $-18.2M | ||
| Q3 22 | $-20.2M | — | ||
| Q2 22 | $-65.8M | — |
自由现金流IMVTMAAS
| Q1 24 | $-59.8M | — | ||
| Q4 23 | $-47.2M | — | ||
| Q3 23 | $-60.1M | — | ||
| Q2 23 | $-47.4M | — | ||
| Q1 23 | $-55.8M | — | ||
| Q4 22 | $-46.5M | $-18.3M | ||
| Q3 22 | $-20.2M | — | ||
| Q2 22 | $-65.9M | — |
自由现金流率IMVTMAAS
| Q1 24 | -714.4% | — | ||
| Q4 23 | -528.7% | — | ||
| Q3 23 | -1682.4% | — | ||
| Q2 23 | -1166.4% | — | ||
| Q1 23 | -1604.0% | — | ||
| Q4 22 | -1579.2% | -184.4% | ||
| Q3 22 | -1751.9% | — | ||
| Q2 22 | — | — |
资本支出强度IMVTMAAS
| Q1 24 | 1.8% | — | ||
| Q4 23 | 1.5% | — | ||
| Q3 23 | 1.0% | — | ||
| Q2 23 | 1.1% | — | ||
| Q1 23 | 0.7% | — | ||
| Q4 22 | 3.3% | 1.0% | ||
| Q3 22 | 2.7% | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMVT
暂无分部数据
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
